HIMS Down 53%, Target Up 20%: How to Spot Real Value in a Market Selloff

Two Stocks Moving in Opposite Directions

In early 2026, two stocks painted a striking contrast in the US market. HIMS cratered 53.5% year-to-date while Target (TGT) rallied over 20%. Same market, same macro backdrop. So why the divergence?

The answer comes down to a distinction most investors get wrong: "cheaper" and "undervalued" are not the same thing.

A stock that's been cut in half isn't automatically a buy. A stock that's risen 20% isn't automatically expensive. What matters is what you're paying relative to the cash flows the business generates. Here's how the numbers break down for both.

HIMS: A Healthcare Platform in the Eye of the Storm

HIMS & Hers delivers hair loss treatments, weight loss medications, and mental health therapy straight to your door—no doctor's office required. Market cap: $3.86 billion. Enterprise value: $4.88 billion.

The crash has a clear trigger.

In February 2026, the FDA declared HIMS's cheaper weight loss drug versions to be illegal copies. Novo Nordisk (NVO) filed a lawsuit. Major pharmaceutical companies began selling directly to consumers, cutting HIMS out of the equation entirely. The stock collapsed.

But the numbers beneath the headline tell a more nuanced story.

Metric	Value
Market Cap	$3.86B
Revenue (TTM)	$2.21B
Free Cash Flow (1yr)	$120M
FCF Multiple	32x
Gross Margin	75%
Share Dilution (5yr)	+24%

That 75% gross margin stands out. It means as revenue scales, profits and cash flow can ramp up fast. This isn't a low-margin business struggling to turn a dollar of revenue into a dime of profit.

And the weight loss segment? It's only about 30% of total revenue. Skincare, mental health, and men's health products make up the remaining 70% and are growing steadily. The company holds over $1 billion in cash, making near-term bankruptcy unlikely. International expansion into Australia, the UK, and Germany could add $200 million in new revenue this year alone.

What Valuation Analysis Shows

Using a 10-year discounted framework with conservative assumptions (8% revenue growth, 10% profit margin, 16x PE), fair value comes to $20—above the current $15. Mid-case assumptions (12.5%, 17%, 19x) yield $57. Bull case (20%, 25%, 22x) gets you to $160.

I'll be honest: this is a company where five years from now, it could be ten times larger or completely gone. Both outcomes would make sense.

But investing is about expected value. If there's a 10% chance of a 50x payoff, you take that bet every time. If there's a 10% chance of merely doubling your money, you pass. At $15, the question is where HIMS falls on that spectrum.

The catch is dilution. Shares outstanding grew 24% over five years. Even if the company executes perfectly, existing shareholders are getting their slice of the pie quietly shrunk. That's the silent killer in investing.

Target (TGT): The Quiet Comeback of American Retail

Market cap: $53 billion. One of the most recognizable retail brands in America.

After a brutal 2025, the stock bounced back over 20% in early 2026, driven by new CEO Michael Fiddelke's appointment and an aggressive $5 billion modernization plan.

The bull case has specific data behind it:

• AI-powered inventory management reducing stockouts on popular items
• Same-day delivery growing over 35%
• Target Circle 360 membership driving higher repeat visits
• A 10-year plan to open 300 new stores (30 in 2026)
• Private label brands (Good & Gather, Cat & Jack, Threshold) boosting margins
• ChatGPT-powered shopping tools enhancing the online experience

Metric	Value
Market Cap	$53B
Annual Free Cash Flow	$3B
Dividend Yield	4%
Dividend/FCF Ratio	~66%
5yr Revenue Growth Outlook	2–3.5%
5yr EPS Growth Outlook	6–16%

A 2–3% revenue growth rate might look unimpressive. But here's the thing: if you pay the right price, you can make excellent returns even on slow growers. That's the core principle of value investing. Paying 10x earnings for a company growing 3% per year can beat paying 100x earnings for one growing 30%.

What Valuation Analysis Shows

With 10-year assumptions of 2–4% revenue growth, 3–5% profit margins, and 17–23x PE, fair value ranges from a conservative $106 to a mid-case $168 to a bull-case $250. At its 52-week low of $82, the stock was trading at nearly half of mid-case fair value.

One concern: dividend sustainability. Paying out two-thirds of free cash flow while simultaneously investing $5 billion stretches the balance sheet. A dividend cut isn't impossible, though management will likely try to maintain it to keep income-focused investors on board.

The Price You Pay Determines Everything

These two stocks illustrate one fundamental truth.

The same company can be a great investment or a terrible one depending entirely on what you pay for it. HIMS is risky, but at $15, the expected value math might work. Target is stable, but buying at the top compresses your returns to nothing.

Most investors lose money because they obsess over finding the next big winner. The best investors do the opposite—they focus on eliminating losers first. And the tool for that job is always valuation.

FAQ

Q: Could the weight loss drug lawsuit destroy HIMS entirely? A: The weight loss segment accounts for roughly 30% of total revenue. Even if it vanishes completely, the remaining 70% (skincare, mental health, men's health) continues growing independently. The real risk is whether the $1 billion cash reserve gets drained by legal costs.

Q: Is Target's 4% dividend safe? A: With about 66% of free cash flow going to dividends and a $5 billion capital plan ahead, sustainability is tight. A long-term dividend cut is possible, though management has strong incentives to maintain it.

Q: Should you always buy stocks that have dropped significantly? A: No. A lower price doesn't equal undervaluation. The key question is whether you're paying a reasonable price for the company's future cash flows. A stock can drop 50% and still be expensive. It can rise 20% and still be cheap.